Prithviraj Bose

Prithviraj Bose is a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he specializes in hematological malignancies and myeloid neoplasia. His research focuses on the clinical pharmacology and pharmacotherapy of myeloproliferative neoplasms, particularly myelofibrosis and systemic mastocytosis, with recent breakthroughs including a Phase I study combining ruxolitinib with the CDK4/6 inhibitor abemaciclib and the 4-year follow-up of avapritinib in advanced systemic mastocytosis. He has also investigated sotatercept for pulmonary hypertension associated with myeloproliferative neoplasms and venetoclax-based therapies for acute myeloid leukemia. His work spans immunology and pathology, contributing to optimized diagnostic assays such as the super RCA KIT D816V test, and he has led international trials in chronic lymphocytic leukemia.